X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NBI-74788 (crinecerfont) is a CRF1 receptor inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of congenital adrenal hyperplasia via oral capsule.
Lead Product(s): Crinecerfont
Therapeutic Area: Genetic Disease Product Name: NBI-74788
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
NBI-74788 (crinecerfont) is an investigational, oral, selective CRF1 antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia.
Lead Product(s): Crinecerfont
Therapeutic Area: Genetic Disease Product Name: NBI-74788
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
NBI-74788 (crinecerfont) s an investigational, oral, selective CRF1 antagonist being developed to reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia.
Lead Product(s): Crinecerfont
Therapeutic Area: Genetic Disease Product Name: NBI-74788
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Changes in Adrenal and Gonadal Androgens After 14-Day Treatment with CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men with Classic 21-Hydroxylase Deficiency.
Lead Product(s): Crinecerfont
Therapeutic Area: Genetic Disease Product Name: NBI-74788
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2021
Details:
Phase II clinical study of crinecerfont (NBI-74788), demonstrated meaningful reductions in all three key disease hormone markers in adult patients with classic congenital adrenal hyperplasia (CAH), a genetic disorder affecting the adrenal glands.
Lead Product(s): Crinecerfont
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Following the cancellation of the annual meeting of the Endocrine Society in March, the company plans to share the full data set from all four patient cohorts at the newly organized ENDO in June.
Lead Product(s): Crinecerfont
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
